Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study.

ABSTRACT:

Background

COVID-19 disproportionately impacted patients with cancer as a result of direct infection, and delays in diagnosis and therapy. Oncological clinical trials are resource-intensive endeavors that could be particularly susceptible to disruption by the pandemic, but few studies have evaluated the impact of the pandemic on clinical trial conduct.

Patients and methods

This prospective, multicenter study assesses the impact of the pandemic on therapeutic clinical trials at two large academic centers in the Northeastern United States between December 2019 and June 2021. The primary objective was to assess the enrollment on, accrual to, and activation of oncology therapeutic clinical trials during the pandemic using an institution-wide cohort of (i) new patient accruals to

SUBMITTER: Bakouny Z 

PROVIDER: S-EPMC9197329 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature